Zydus Lifesciences reported a strong finish to the fiscal year, with Q4 FY26 revenue reaching Rs. 75,870 million, a 16% year-on-year increase. The company achieved a 20% growth in EBITDA and an EBITDA margin of 33.7%. Alongside robust financial results, the Board recommended a 100% dividend for FY2025-26 and approved a significant equity share buyback program of up to Rs. 11,000 million at Rs. 1,150 per share.
Financial Performance Overview
Zydus Lifesciences delivered impressive growth for the quarter and full year ending March 31, 2026. For the full fiscal year, the company recorded consolidated revenues of Rs. 2,71,484 million, reflecting a 17% growth compared to the previous year. Net profit (adjusted) for the full year stood at Rs. 54,564 million, marking a 15% increase.
Strategic Shareholder Returns
Following the successful fiscal performance, the Board of Directors has taken proactive measures to enhance shareholder value. This includes a recommended 100% dividend for FY2025-26. Furthermore, the company has announced an equity share buyback program valued at up to Rs. 11,000 million, priced at Rs. 1,150 per share, which represents a 16% premium to the closing price of May 18, 2026.
Business Segment Performance
The company’s growth remains broad-based across its diverse business units. The Pharma Business continues to be the dominant segment, accounting for 76% of Q4 revenues. Key drivers included a 14% year-on-year growth in India Formulations and strong international expansion. The Consumer Wellness segment saw a notable 61.1% year-on-year revenue jump to Rs. 14,633 million in Q4, while the MedTech division also posted strong results.
Innovation and Pipeline Milestones
Zydus maintains a focus on future growth through a robust R&D pipeline. The company invested Rs. 22,732 million in R&D throughout FY26. Major R&D highlights include the approval of Desidustat in China for renal anemia, the initiation of Phase III clinical trials for biosimilar antibody drug conjugates, and the acquisition agreement for Assertio Holdings, Inc. for US$ 166 million to bolster its US specialty footprint.
Source: BSE
